Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 3/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | PTAFR | P25105 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666625 | 0.94 | SLC6A4 (0.47) | KHKPTK2HRH3SLC6A4KCNH2 | |
| SCHEMBL3737493 | 0.94 | SLC6A4 (0.47) | KHKPTK2HRH3SLC6A4KCNH2 | |
| SCHEMBL3725620 | 0.88 | PTAFR (0.44) | KHKPTK2HRH3SLC6A4PTAFR | |
| SCHEMBL4937472 | 0.84 | HRH3 (0.58) | HRH3PTAFRKCNH2 | |
| SCHEMBL3733490 | 0.83 | HRH3 (0.59) | HRH3KCNH2 | |
| SCHEMBL4945186 | 0.83 | HRH3 (0.59) | HRH3KCNH2 | |
| SCHEMBL3725332 | 0.82 | PTAFR (0.52) | PTK2HRH3SLC6A4PTAFRKCNH2 | |
| SCHEMBL8366144 | 0.82 | KHK (0.42) | KHKHRH3PTAFRKCNH2MGAM | |
| SCHEMBL3722716 | 0.81 | HRH3 (0.66) | HRH3KCNH2 | |
| SCHEMBL3668809 | 0.80 | USP30 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101778838-A | Azacyclylbenzamide derivatives as histamine-3 antagonists | WYETH CORP | 2010-07-14 | — | — | CN | claimed |
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | claimed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | claimed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | claimed |
| CN-101778838-A | Azacyclylbenzamide derivatives as histamine-3 antagonists | WYETH CORP | 2010-07-14 | — | — | CN | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | KHK 4389/4885PTK2 3820/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.